Innate Pharma S.A./€IPH

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Innate Pharma S.A.

Innate Pharma S.A. is a clinical-stage biotechnology company specializing in immuno-oncology, focusing on developing therapeutic antibodies that engage the innate immune system to treat cancer. Its pipeline includes lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous and peripheral T-cell lymphomas, and monalizumab, an immune checkpoint inhibitor in Phase III trials for advanced solid tumors. Founded in 1999 and headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, the company has established collaborations with biopharmaceutical firms such as AstraZeneca and Sanofi. Innate Pharma's proprietary ANKET® platform focuses on developing multi-specific NK cell engagers, positioning the company in the field of natural killer cell therapeutics.

Ticker

€IPH

Primary listing

PAR

Industry

Biotechnology
Headquarters

Employees

181

IPH Metrics

BasicAdvanced
€177M
-
-€0.61
0.96
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €IPH

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs